User profiles for Mary Ramsay
 | Mary RamsayVerified email at hpa.org.uk Cited by 51124 |
[HTML][HTML] Duration of protection against mild and severe disease by Covid-19 vaccines
Background Vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2),
the virus that causes coronavirus disease 2019 (Covid-19), have been used since …
the virus that causes coronavirus disease 2019 (Covid-19), have been used since …
[HTML][HTML] Robust SARS-CoV-2-specific T cell immunity is maintained at 6 months following primary infection
…, G Amirthalingam, K Brown, ME Ramsay… - Nature …, 2021 - nature.com
The immune response to SARS-CoV-2 is critical in controlling disease, but there is concern
that waning immunity may predispose to reinfection. We analyzed the magnitude and …
that waning immunity may predispose to reinfection. We analyzed the magnitude and …
Effectiveness of maternal pertussis vaccination in England: an observational study
Background In October, 2012, a pertussis vaccination programme for pregnant women was
introduced in response to an outbreak across England. We aimed to assess the vaccine …
introduced in response to an outbreak across England. We aimed to assess the vaccine …
Planning, registration, and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story
The introduction of meningococcal C conjugate (MCC) vaccine in the UK in November 1999
as a routine 3 dose infant immunisation course, with a single catch-up dose for all children …
as a routine 3 dose infant immunisation course, with a single catch-up dose for all children …
Factors underlying parental decisions about combination childhood vaccinations including MMR: a systematic review
Suboptimal childhood vaccination uptake results in disease outbreaks, and in developed
countries is largely attributable to parental choice. To inform evidence-based interventions, we …
countries is largely attributable to parental choice. To inform evidence-based interventions, we …
[HTML][HTML] Effectiveness of Covid-19 vaccines against the B. 1.617. 2 (Delta) variant
Background The B.1.617.2 (delta) variant of the severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (Covid-19), has …
coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (Covid-19), has …
[HTML][HTML] Effectiveness of Covid-19 vaccines against the B. 1.617. 2 (Delta) variant
Background The B. 1.617. 2 (delta) variant of the severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (Covid-19), has …
coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (Covid-19), has …
[HTML][HTML] Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV …
Background Few data exist on the comparative safety and immunogenicity of different
COVID-19 vaccines given as a third (booster) dose. To generate data to optimise selection of …
COVID-19 vaccines given as a third (booster) dose. To generate data to optimise selection of …
Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England …
Objective To estimate the real world effectiveness of the Pfizer-BioNTech BNT162b2 and
Oxford-AstraZeneca ChAdOx1-S vaccines against confirmed covid-19 symptoms (including the …
Oxford-AstraZeneca ChAdOx1-S vaccines against confirmed covid-19 symptoms (including the …
[HTML][HTML] Covid-19 vaccine effectiveness against the Omicron (B. 1.1. 529) variant
Background A rapid increase in coronavirus disease 2019 (Covid-19) cases due to the
omicron (B.1.1.529) variant of severe acute respiratory syndrome coronavirus 2 in highly …
omicron (B.1.1.529) variant of severe acute respiratory syndrome coronavirus 2 in highly …